Michael D. Lockshin, MD

Dr. Lockshin graduated from Harvard College and Harvard Medical School; he did his residencies at Second (Cornell) Medical Service at Bellevue Hospital and Memorial-Sloan Kettering Hospital, and his rheumatology fellowship at Columbia-Presbyterian Hospital. A member of the faculty of Cornell Medical College and a staff rheumatologist at Hospital for Special Surgery and New York Hospital from the 1970s to 1989, he became Extramural Director, then Acting Director of the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases in 1989. He returned to Hospital for Special Surgery in April 1997, and is now the director of the Barbara Volcker Center for Women and Rheumatic Disease at Hospital for Special Surgery and professor of medicine and obstetrics-gynecology at Weill-Cornell Medical College. He is the author of nearly 300 research papers, book chapters, and books, most on the topic of lupus, pregnancy, antiphospholipid syndrome, and sex differences in disease.

Appointments

Professor of Medicine and OB-GYN, Weill Medical College of Cornell University

Attending Physician, Hospital for Special Surgery

Director, Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery

Co-Director, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery

Specialty
Rheumatology

Certification

Internal Medicine, 1969

Rheumatology, 1972

Chairman, Rheumatology Subspecialty Board, 1983-86

State Licensure
New York

Education

MD, 1963, Harvard Medical School, Cambridge, Massachusetts, US

Residency

Second (Cornell) Medical Service, US

Bellevue Hospital, US

Memorial Sloan-Kettering Hospital, US

Fellowship

Columbia-Presbyterian Medical Center, US

Michael D. Lockshin, MD is the author of the following articles on HSS.edu:

For Patients

• Reflections on the Withdrawal of Vioxx from the Market
• FDA Alert Regarding Lupus Medication: an HSS Rheumatology Perspective
• Effects of Fluvastatin on Proinflammatory and Prothrombotic markers in Antiphospholipid Syndrome
• Special Report: Perspective on the recent data about celecoxib (Celebrex) and naproxen (Aleve)
• Bextra® Withdrawal from the Market - HSS Physicians Reflect on Options for Patients in Pain
• Hospital for Special Surgery Doctors Available to Comment on Withdrawal of Vioxx®
• Gender and Rheumatoid Arthritis
• An Overview of Lupus Research: Where We’ve Been and Where We’re Going
• “Unlocking the Mystery of Lupus: Lupus & the Heart” FAQs
• COX-2 Inhibitor Safety: HSS Physicians Reflect on the Recommendations of the FDA Advisory Panel
• Lupus Vasculitis and Blocked Blood Vessels
• Targets for New SLE Treatments
• Vaccinations and Rheumatic Disease
• Update on Smallpox and Flu Vaccinations
• Laboratory Tests in Lupus
• Antiphospholipid Antibody Syndrome - In-Depth Overview
• Autoimmune Disease: Does Sex Matter?
• "Antiphospholipid Syndrome: Essential Information and Support" FAQs
• An In-Depth Overview of Systemic Lupus Erythematosus

For Professionals

• FDA Alert Regarding Lupus Medication: an HSS Rheumatology Perspective
• Effects of Fluvastatin on Proinflammatory and Prothrombotic markers in Antiphospholipid Syndrome
• CPC: Primary Antiphospholipid Syndrome Presenting as HELLP Syndrome
• Special Report: Perspective on the recent data about celecoxib (Celebrex) and naproxen (Aleve)
• Bextra® Withdrawal from the Market - HSS Physicians Reflect on Options for Patients in Pain
• Update on Antiphospholipid Antibody - In-Depth Overview for Physicians
• COX-2 Inhibitor Safety: HSS Physicians Reflect on the Recommendations of the FDA Advisory Panel
• Vaccinations and Rheumatic Disease
• Update on Antiphospholipid Antibody

Special Expertise

Gender and rheumatic disease

Pregnancy and rheumatic disease

Antiphospholipid antibody syndrome

Neurological SLE

Awards

Various national offices, national and international visiting professorships.

Institute of Medicine Committee

Selected Publications
For more publications, please see the PubMed listing.

Clinical Trials

• Cognitive Dysfunction, Diffusion Tensor Imaging and Functional Magnetic Resonance Imaging (MRI) in Antiphospholipid Antibody (aPL)-negative Systemic Lupus Erythematosus (SLE) versus aPL-positive non-SLE Patients
• Effects of Fluvastatin on Proinflammatory and Prothrombotic markers in Antiphospholipid Syndrome
• A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 Week Study to Evaluate the Efficacy and Safety of Belimumab (GHS1006, LymphoStat-B), A fully Human monoclonal Anti-BlyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE).
• RITAPS: A Pilot Study Of Rituximab For The Anticoagulation-Resistant Manifestations Of Antiphospholipid Syndrome (APS)
• PROMISSE: Predictors of Pregnancy Outcome: Biomarkers in Anti-Phospholipid Antibody Syndrome (APS) and Systemic Lupus Erythematosus (SLE)
• Pilot and Feasibility Study of Modafinil Treatment to Improve Cognitive Efficiency in SLE Patients
• LUNAR: A phase III, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of rituximab in subjects with class III or IV lupus nephritis
• EXPLORER: A randomized, double-blind, placebo controlled, multicenter, phase II/III study to evaluate the efficacy and safety of rituximab in subjects with moderate to severe systemic lupus erythematosus

Specialized Centers
Barbara Volcker Center for Women and Rheumatic Diseases